ClinicalTrials.gg
RecruitingNCT06420167FLORALUpdated Jun 26, 2026

DapagliFLOzin in Renal AL Amyloidosis (FLORAL)

A Phase 2 interventional study of Dapagliflozin in Renal AL Amyloidosis, sponsored by Barbara Ann Karmanos Cancer Institute. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-26.

Sponsored by Barbara Ann Karmanos Cancer Institute · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 151 studies in Immunoglobulin Light-chain Amyloidosis with a site in United States — 23 open to participants now, 35 under way, 3 of them phase 3. Immunoglobulin Light-chain Amyloidosis · United States.

Planned enrollment
85th of 114
20 · median 38
Started
2024
with 7 others
Phase 2
49 of 151
5 open now
Primary completion
2027-04
later than 12 of 34 live
Registered
142nd of 151
by date
Lead sponsor
7 of 151
Barbara Ann Karmanos Cancer Institute

Among the 151 studies in Immunoglobulin Light-chain Amyloidosis with a site in United States, this one is the 85th largest by planned enrollment of the 114 interventional ones that give a count, is one of 8 that started in 2024, is one of 49 in phase 2, reaches primary completion later than 12 of the 34 other live ones, and was the 142nd registered.

Immunoglobulin Light-chain Amyloidosis

239 studies on the registry are indexed under Immunoglobulin Light-chain Amyloidosis; 63 are open to participants now.

Browse Immunoglobulin Light-chain Amyloidosis studies →

Open to participants now

23 of the 151 studies in Immunoglobulin Light-chain Amyloidosis with a site in United States are open now. Recruiting first, the newest first:

17 more — sign in →

All 23 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 49 Immunoglobulin Light-chain Amyloidosis studies recruiting now, 34 (69%) set no upper age limit and 3 (6%) stop at 75 or younger; 3 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 151 studies in Immunoglobulin Light-chain Amyloidosis with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if an oral drug called dapagliflozin is safe and can reduce high protein levels in the urine of patients with renal amyloid light-chain (AL) amyloidosis using a decentralized study design.

Participants will be:

  • screened for the trial via an online platform
  • contacted by study personal to obtain electronic consent
  • enrolled in the trial if eligible and consented
  • contacted by study personal for further instructions and directions
  • sent dapagliflozin oral medication (supplied by the site pharmacy)
  • followed up regularly with the study team via telemedicine or other online avenues
  • monitored using lab work, inquiries about side effects and assessment of protocol adherence at 1 month, 3 months and 6 months
  • continue treatment for 6 months
Read the detailed description
  1. Participants are recruited by one of the following methods:

    1. Self-referral through the website
    2. Receiving recruitment materials from their provider.
  2. Participant visits the prescreening website.

    1. High level prescreening questions are answered by the participant.
    2. If appropriate based on answers to the questions, the participant may provide their contact information for follow up by the study team.
  3. Study team contacts potential participants to review the study and explain next steps
  4. Participant is provided with the link and password to view the video and sign the consent via Adobe Sign
  5. An investigator will meet virtually with the participant to obtain medical history information, concomitant medications, and performance status (screening visit)
  6. Once the participant passes screening in step 5, an order will be sent to the participant for the remaining screening labs to be done at a local laboratory that is covered by their insurance
  7. The lab will fax results to the site
  8. After review of eligibility and the study team will proceed with enrolling the participant if appropriate
  9. The participant will proceed to the baseline visit (telehealth for any portion that can be done via phone/video and order for lab tests as previously described) if needed to comply with the protocol calendar/window.
  10. The participant is approved to begin dosing by the investigator
  11. The site will dispense via mail the following:

    1. 4 month's supply of Dapagliflozin
    2. A self-addressed envelope for return of the diary and pill bottles at the end of the dosing period
    3. A weighing scale (if required)
  12. Dosing compliance will be checked during initial study treatment via sharing of pill accountability data or screenshot of paper pill diary
  13. If clinically indicated, labs will be ordered and run more frequently to assess for toxicity.
  14. Visits 3, 4, and 5 will be conducted in the same manner as described above.
  15. All pill bottles and diaries (if paper version is used) will be returned via the provided envelope
03

Conditions studied

  • Renal AL Amyloidosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of signed and dated form.
  • Stated willingness to comply with study procedures, including remote telehealth consultations with the study team, confirming availability, and agreeing to use mobile/web applications for study purposes.
  • Age ≥18 years.
  • Histopathologic diagnosis of renal AL amyloidosis confirmed by of any tissue and evidence of >1.0 g/day proteinuria without any other identifiable cause.
  • (ECOG) Performance Status (PS) 0, 1 or 2.
  • Plateau in any renal response (i.e., reduction in proteinuria) for at least 3 months prior to enrollment, as determined by the enrolling physician.
  • Residence in the state of Michigan.

Exclusion criteria

Exclusion Criteria:

  • Either ongoing induction with anti-plasma cell therapy or ongoing post- induction maintenance for \<6 months prior to enrollment.
  • Diagnosis of symptomatic multiple myeloma, including presence of lytic bone disease, plasmacytomas, ≥60% plasma cells in the bone marrow, or hypercalcemia, either currently or in the past.
  • Women of (i.e., those who have not undergone chemical or surgical sterilization or are not ) and who are unwilling to use a medically accepted and reliable form of while participating in the study and for 2 weeks following the last dose of study medication, as determined by the investigator, or have a positive pregnancy test at the time of enrolment or are currently breastfeeding.
  • Known allergic reactions to components of the dapagliflozin.
  • Treatment requiring type 1 or type 2 diabetes mellitus.
  • Baseline \<25 mL/min/1.73m2.
  • Acute or chronic liver disease with severe impairment of liver function (e.g., ascites, esophageal varices or coagulopathy)
  • Current or previous use of any SGLT2i.
  • Initiation or dose modification of angiotensin converting enzyme inhibitors (ACE inhibitors) and angiotensin receptor blockers (ARBs) \<3 months prior to enrollment.
  • Active requiring treatment (other than AL amyloidosis and non-melanoma skin cancers).
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Dapagliflozin

    Dapagliflozin 10mg orally, daily for 6 months

    Drug: Dapagliflozin

Interventions

  • 10mg orally once daily

    Also known as: BMS-512148, Forxiga® / Farxiga®

06

What researchers measure

Primary outcomes

  1. Proportion of patients achieving 30% reduction in daily proteinuria.

    A patient will be considered to have achieved the desired urine protein reduction if a 30% reduction in 24-hour albuminuria occurs at any point during the six-month period from the initiation of dapagliflozin therapy. The proportion of patients achieving this reduction will be calculated as the ratio of the total number of patients who experienced the reduction to the total number of evaluable patients.

    Time frame: Up to Month 6

Secondary outcomes

  1. Completion rate of tele-visits

    The completion rate of tele-visits, including post-trial feedback, will be calculated as the ratio of completed tele-visits to scheduled tele-visits.

    Time frame: Up to Month 6

Other outcomes

  1. Proportion of patients experiencing any of the following: (1) sustained decline in eGFR, (2) onset of ESRD, or (3) death from a renal disease-related or cardiovascular cause.

    A patient's status will be recorded as 'yes' if any of the following three events occur at any time during the 6 months of study therapy: a sustained ≥50% decline in estimated glomerular filtration rate (eGFR); the onset of dialysis-requiring end- stage renal disease (ESRD); or death from a renal disease-related or cardiovascular cause. Otherwise, the status will be marked as 'no'.

    Time frame: Up to Month 6

  2. Incidence rate of developing dialysis dependent ESRD in patients with Pavia Renal AL Stage II or III involvement.

    The onset of ESRD in patients with Pavia Renal Stage II or III involvement will be recorded as binary (yes vs. no).

    Time frame: Up to Month 6

07

Study locations

1 of 1 sites recruiting
  • Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
    Recruiting
    • Christiane Houde · ContactHoudec@karmanos.org · 3135768673
    • Jeffrey Zonder · Contactzonderj@karmanos.org · 3135768732
    • Jeffrey Zonder, M.D. · Principal investigator
    • Andrew Kin, M.D. · Sub investigator
    • Aditi Sharma, M.D. · Sub investigator
    • Joel Topf, M.D. · Sub investigator
    • Craig Cole, M.D. · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Apr 2027, 33 months after the start.

Of 31 phase 2 interventional studies under Immunoglobulin Light-chain Amyloidosis, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 89. This study's planned 33 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2024
First posted
May 17, 2024
StartActual
Jul 11, 2024
Primary completionEst.
Apr 2027
CompletionEst.
Apr 2028
Last update
Jun 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06420167
Responsible party
Jeffrey Zonder (Principal Investigator, Multiple Myeloma Multidisciplinary team leader, M.D., Barbara Ann Karmanos Cancer Institute) — Principal investigator
First posted
May 17, 2024
Start date
Jul 11, 2024
Primary completion
Apr 2027 (estimated)
Completion
Apr 2028 (estimated)
Last update
Jun 26, 2026

Study contacts

Christiane Houde
Contact
Houdec@karmanos.org
3135768673
Jeffrey Zonder, M.D.
Contact
zonderj@karmanos.org
3135768732
Jeffrey Zonder, M.D.
principal investigator · Barbara Ann Karmanos Cancer Institute

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dapagliflozin

Start the discussion